Nemaura Med Inc (NMRD) 1.1000 $NMRD
Nemaura Medical to Present Positive Interim Clinical Trial Results of its sugarBEAT(R) System at the Marcum Microcap Conference, New York
Business Wire - Wed May 27, 7:00AM CDT
Nemaura Medical Inc. (OTC BB: NMRD), ("Nemaura"
, a medical device company developing the sugarBEAT(R) CGM System as a non-invasive, wireless continuous glucose monitoring system, announced today that it has conducted an interim analysis of clinical data from its ongoing 540 patient day clinical program of Type I and Type II diabetic Patients. Nemaura will present these findings at the Marcum Microcap Conference in New York on Thursday 28th May 2015.
Nemaura Medical to Present at the 2015 Marcum Microcap Conference May 28
Business Wire - Tue May 19, 11:22AM CDT
Nemaura Medical Inc. (OTC BB: NMRD), a leading developer of minimally-invasive transdermal diagnostic technologies, announced today that Dr. D F Chowdhury, CEO, and Bashir Timol, Commercial Director, will be presenting at the 2015 Marcum Microcap Conference, which will take place May 27th to May 28th at the Grand Hyatt Hotel in New York City.
Global Blood Glucose Meters Pipeline Review 2015
M2 - Tue Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhqtk3/blood_glucose) has announced the addition of the "Blood Glucose Meters - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key blood glucose meters pipeline products. Scope: - Extensive coverage of the Blood Glucose Meters products under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Blood Glucose Meters and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry The report enables you to: - Formulate significant competitor information, analysis, and insights to improve R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of Blood Glucose Meters under development - Develop market-entry and market expansion strategies - Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline - In-depth analysis of the product's current stage of development, territory and estimated launch date Companies Featured - Partial List - C8 MediSensors, Inc. - GlucoSet AS - Glucovation, Inc. - GluMetrics, Inc. - GluSense Ltd. - GlySens Incorporated - GlySure Ltd - Grove Instruments Inc. - Hygiena, LLC - Hypo-Safe A/S - Mendor Oy - MicroCHIPS, Inc. - mobiLIFE - Nagasaki University - Nemaura Medical Inc - Newton Photonics Inc - Northwestern University - NovioSense B.V. - Optiscan Biomedical Corporation - Pepex Biomedical, Inc. - Pignolo SpA - PositiveID Corporation - Quick, LLC - Senseonics, Incorporated - Sentec Ag - Senzime AB - Socrates Health Solutions, Inc. - University of Western Ontario - Vytrace, Inc. - Xhale, Inc. For more information visit http://www.researchandmarkets.com/research/vh...od_glucose
Nemaura Medical to Present Positive Interim Clinical Trial Results of its sugarBEAT(R) System at the Marcum Microcap Conference, New York
Business Wire - Wed May 27, 7:00AM CDT
Nemaura Medical Inc. (OTC BB: NMRD), ("Nemaura"
, a medical device company developing the sugarBEAT(R) CGM System as a non-invasive, wireless continuous glucose monitoring system, announced today that it has conducted an interim analysis of clinical data from its ongoing 540 patient day clinical program of Type I and Type II diabetic Patients. Nemaura will present these findings at the Marcum Microcap Conference in New York on Thursday 28th May 2015. Nemaura Medical to Present at the 2015 Marcum Microcap Conference May 28
Business Wire - Tue May 19, 11:22AM CDT
Nemaura Medical Inc. (OTC BB: NMRD), a leading developer of minimally-invasive transdermal diagnostic technologies, announced today that Dr. D F Chowdhury, CEO, and Bashir Timol, Commercial Director, will be presenting at the 2015 Marcum Microcap Conference, which will take place May 27th to May 28th at the Grand Hyatt Hotel in New York City.
Global Blood Glucose Meters Pipeline Review 2015
M2 - Tue Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhqtk3/blood_glucose) has announced the addition of the "Blood Glucose Meters - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key blood glucose meters pipeline products. Scope: - Extensive coverage of the Blood Glucose Meters products under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Blood Glucose Meters and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry The report enables you to: - Formulate significant competitor information, analysis, and insights to improve R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of Blood Glucose Meters under development - Develop market-entry and market expansion strategies - Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline - In-depth analysis of the product's current stage of development, territory and estimated launch date Companies Featured - Partial List - C8 MediSensors, Inc. - GlucoSet AS - Glucovation, Inc. - GluMetrics, Inc. - GluSense Ltd. - GlySens Incorporated - GlySure Ltd - Grove Instruments Inc. - Hygiena, LLC - Hypo-Safe A/S - Mendor Oy - MicroCHIPS, Inc. - mobiLIFE - Nagasaki University - Nemaura Medical Inc - Newton Photonics Inc - Northwestern University - NovioSense B.V. - Optiscan Biomedical Corporation - Pepex Biomedical, Inc. - Pignolo SpA - PositiveID Corporation - Quick, LLC - Senseonics, Incorporated - Sentec Ag - Senzime AB - Socrates Health Solutions, Inc. - University of Western Ontario - Vytrace, Inc. - Xhale, Inc. For more information visit http://www.researchandmarkets.com/research/vh...od_glucose
